Denosumab in Metabolic Bone Disease in Chronic Intestinal Failure Patients
Denosumab in Metabolic Bone Disease in Chronic Intestinal Failure Patients
Low bone mineral density (BMD) is commonly reported in patients receiving home parenteral
 nutrition (HPN). Denosumab represent a new drug, which helped to prevent osteoclast. The aim
 of the study was to assess its value in chronic intestinal failure patients.
Low bone mineral density (BMD) is commonly reported in patients receiving home parenteral
 nutrition (HPN). Oral and intravenous calcium, vitamin D and bisphosphonates have been
 commonly used to treat BMD, but their efficiency is may be inadequate due to limited
 absorption and compliance. Denosumab represent a new drug, which helped to prevent osteoclast
 development and activation, hence decreased bone resorption in some studies. The aim of the
 study was to assess its value in chronic intestinal failure patients receiving HPN.

 Between November 2011 and March 2013 denosumab was administered to 16 HPN patients (9 F, 7 M
 mean age 55.4) with intestinal failure. Regional dual-energy x-ray absorptiometry of spine
 and hip were performed before the therapy was initiated, and after 12 months. BMD, T-score
 and Z-score were measured.
Inclusion Criteria:

 -  intestinal failure requiring home parental nutrition

 -  bone disease measurement

 Exclusion Criteria:

 -  intestinal failure not requiring HPN

 -  diagnostic modalities impossible